MetaCap

GRI Bio Inc. (GRI)

NASDAQ: GRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.120.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GRI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$20.57
52-week range
1.09 – 64.12
Day range
1.12 – 1.25
Volume / Avg
25.07K / 218.31K
Beta
—

52-week range

$1.09$64.12

GRI stock today

GRI Bio (GRI) closed at $1.12 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 25.07K shares changing hands, about 11% of the average daily volume. At this level, GRI sits near the bottom of its 52-week range of $1.09 to $64.12: 98.3% below the high and 2.8% above the low.

GRI Bio trades at 0.1x its trailing twelve-month earnings per share of $20.57.

Summary generated from market data by MetaCap's automated system. Methodology

About GRI Bio

Company profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.

Industry
Biotechnology: Pharmaceutical Preparations
Headquarters
La Jolla, CA
Employees
3
IPO year
2021
Website
gribio.com

Financial highlights

Full financials

GRI Bio reported a net loss of $12.0 million, compared with a loss of $8.2 million a year earlier. Diluted earnings per share came in at -$121.80.

GRI Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue————$0
Growth————-100.00%
Net income$-11.96M$-8.21M$-13.04M$-3.22M$-9.30M
EPS (diluted)$-121.80$-1,545.55$-5,018.09$-24.95$-1.42

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$18.50+1551.79%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $27.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.69 vs $-0.84
Surprise
+17.86%

GRI Bio peers

Health Care sector
GRI peer companies
CompanyPrice% ChgMarket capCompare
RDHLRedhill Biopharma Ltd. ADR0.281-13.08%$2.50Mvs GRI
DRMADermata Therapeutics Inc.0.5095-4.23%$2.51Mvs GRI
ONCOOnconetix Inc.2.89-8.54%$2.37Mvs GRI
HCWBHCW Biologics Inc.0.7491+1.90%$2.35Mvs GRI
ERNAErnexa Therapeutics Inc.1.36-16.56%$2.30Mvs GRI
MBIOMustang Bio Inc.0.3541-4.30%$2.69Mvs GRI
TRAWTraws Pharma Inc.0.175-23.91%$2.69Mvs GRI
LABTLakewood-Amedex Biotherapeutics Inc.0.2449+15.03%$2.19Mvs GRI

Indexes, lists and sector

GRI Bio stock FAQ

What is GRI Bio's stock price today?

GRI last traded at $1.12 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

What is GRI's P/E ratio?

GRI trades at a trailing P/E ratio of 0.05.

What is the GRI 52-week high?

The 52-week high for GRI is $64.12 and the 52-week low is $1.09. The stock is currently 98.3% below its high.

Compare GRI